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R. Chen et al. / Biol Blood Marrow Transplant 20 (2014) 1841e18681864developing aGVHD may be started on treatment preemp-
tively. Among biomarkers identiﬁed in current study, only
ST2 was prognostic of aGVHD risk before day þ14 after he-
matopoietic cell transplantation; this is not surprising given
the relatively late (median, 36 days) onset of aGVHD after
NMAT. Clinically relevant prognostic tools proposed in prior
studies consisted of a panel rather than a single biomarker;
therefore, combinations of biomarkers need to be explored
further [1,2,9].
In conclusion, the current study identiﬁed ST2, REG3a,
and elaﬁn as prognostic biomarkers to stratify for risk of
developing aGVHD after Cy/Flu-based NMAT. These results
need to be conﬁrmed in a large independent validation
cohort, ideally among a number of institutions, to establish
clinically useful cut-offs for their future use in clinical trials.
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We previously reported that brentuximab vedotin (BV) enabled successful reduced-intensity allogeneic he-
matopoietic cell transplantation (RIC-alloHCT) in patients with relapsed Hodgkin lymphoma, after a median
follow-up of 14.4 months. We now provide an updated report on 21 patients who were treated from 2009 to
2012 with BV before RIC-alloHCT with a uniform ﬂudarabine/melphalan conditioning regimen and donor
source after a median follow-up of 29.9 months. We have also retrospectively compared the patient char-
acteristics and outcomes of these BV-pretreated patients to 23 patients who received ﬂudarabine/melphalan
RIC-alloHCT without prior BV, in the time period before the drug was available (2003 to 2009). Patients who
were treated with BV before RIC-alloHCT had a lower median hematopoietic cell transplantationespeciﬁc
comorbidity index and a reduced number of peri-transplantation toxicities. There were also improvements in
2-year progression-free survival (59.3% versus 26.1%) and cumulative incidence of relapse/progression (23.8%
versus 56.5%).
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Brentuximab vedotin (BV) is an antibody-drug conjugate of
anti-CD30 antibody and the microtubule-disrupting agent,
monomethyl auristatin E [1]. BV is approved for use in Hodgkin
lymphoma (HL) patients who have failed autologous hemato-
poietic cell transplantation (autoHCT). Phase II studies report
Table 1
Patient, Disease, and Treatment Characteristics
Characteristics BV
N ¼ 21
No-BV
n ¼ 23
Age, median (range), yr 31 (22-55) 37 (16-63)
Disease stage at diagnosis
I-II 9 (43) 11 (48)
III-IV 11 (52) 11 (48)
Unknown 1 (5) 1 (4)
Response to induction
Refractory 5 (24) 7 (30)
Relapsed 16 (76) 16 (70)
No. previous regimens,
median (range)
4 (3-6) 4 (3-6)
Previous regimens
Induction-ABVD 19 (90) 19 (83)
Salvage chemo before
autoHCT
ICE 17 16
ESHAP 2 10
Others 1 2
AutoHCT 19 19
Salvage chemo after autoHCT
ICE 4 3
ESHAP 0 5
Gemcitabine based 14 17
Bendamustine 3 0
Others 4 9
Radiotherapy 10 17
Consolidation 9 12
Treatment for
relapse/refractory
1 5
Time from diagnosis to HCT,
median (range), mo
60.6 (13.8-258.3) 36.4 (13.6-214.7)
Intermittent therapy between
BV and alloHCT
7 N/A
Gemcitabine based 5
ICE 1
Bendamustine 3
XRT 1
No. cycles of BV, median
(range)
7 (2-16) 0
Best response to BV NA
CR 6 (29)
PR 14 (67)
SD/PD 1 (5)
Disease status at end of BV NA
CR 4 (19)
PR 7 (33)
SD/PD 10 (48)
Disease status at HCT
CR 6 (29) 1 (4)
PR 9 (42) 9 (39)
SD/PD 6 (29) 13 (57)
Stem cell source
Bone marrow 1 (5) 3 (13)
Peripheral blood 20 (95) 20 (87)
HCT-CI score, median (range) 0 (0-3) 2 (0-4)
Type of donor
MRD 10 (48) 12 (52)
MUD 11 (52) 11 (48)
GVHD prophylaxis
Tacrolimus/sirolimus 19 (90) 16 (70)
Cyclosporine A/MMF 2 (10) 6 (26)
Tacrolimus/methotrexate 0 (0) 1 (4)
ABVD indicates adriamycin, bleomycin, vinblastine, dacarbazine; ICE,
ifosfamide, carboplatin, etoposide; ESHAP, etoposide, cisplatin, Ara-C,
methylprednisolone; XRT, radiation therapy; PR, partial response; SD, sta-
ble disease; PD, progressive disease; MRD, matched related donor; MUD,
matched unrelated donor; MMF, mycophenolate mofetil.
Data presented are n (%), unless otherwise indicated.
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proﬁle [2,3]. We previously published our ﬁndings on the use
of reduced-intensity (RIC) allogeneic hematopoietic cell
transplantation (alloHCT) in 24 relapsed/refractory patients
with HL [4], yielding a 2-year progression-free survival (PFS) of
27% (95% conﬁdence interval [CI], 22% to 32%). We have also
reported early data showing that BV salvage before RIC-
alloHCT results in a 1-year overall survival (OS) of 100% and
PFS of 92.3% (95% CI, 61.3% to 98.8%) in patients with relapsed
HL [5].We now report on amore homogenous Hodgkin patient
population, with extended follow-up for outcomes of RIC-
alloHCT after BV salvage. Additionally we have retrospectively
compared the outcomes of these patients to a consecutive case
series of BV-naïve patients who underwent RIC alloHCT in the
pre-BV era. Our hypothesis is that BV salvage therapy could
deliver patients who are better candidates for transplantation,
via higher response rates and lower toxicity, thus contributing
to improved outcomes after RIC-alloHCT.
PATIENTS AND METHODS
The City of Hope Institutional Review Board approved the retrospective
analysis of data from a consecutive case series of 23 HL patients who un-
derwent RIC-alloHCT with no prior BV exposure (no-BV group) between
January 2003 and July 2009 (pre-BV era) and a consecutive case series of 21
HL patients who received BV before RIC-alloHCT (BV group) from July 2009
to December 2012. Sixteen of the 21 HL patients who received BV were
enrolled on prospective clinical trials (4 separate trials). None of the 23 HL
patients without prior BV exposure received BV at relapse after RIC-alloHCT.
Eligible patients were  18 years old with histologically conﬁrmed HL
expressing CD30, who had relapsed after previous autoHCT or were not
autoHCT candidates. Patients were excluded if they had received a previous
alloHCT. All patients received ﬂudarabine/melphalan (ﬂudarabine 25 mg/
m2  5 days followed by melphalan 140 mg/m2  1 day) as their trans-
plantation conditioning regimen. Only matched related sibling donor and
matched unrelated donor transplantations were included; haploidentical
and cord blood transplantations were excluded. Comorbid conditions at the
time of alloHCT were scored using the hematopoietic cell trans-
plantationespeciﬁc comorbidity index (HCT-CI) [6]. The Bearman scale [7]
was used to capture toxicities associated with RIC-alloHCT. Baseline pa-
tient characteristics for the 44 patients are summarized in Table 1.
Post-transplantation evaluation of disease status with imaging studies,
bone marrow biopsies, and engraftment analysis occurred at 30 days,
100 days, and 1 year after transplantation and yearly thereafter, or as clin-
ically indicated. HL disease response was scored using standard criteria [8].
OS and PFS probabilities were calculated using Kaplan-Meier [9] (differences
assessed by log-rank test) and cumulative incidence of relapse/progression
and nonrelapse mortality (NRM) were calculated as competing risks [10]
(differences assessed using the Gray method).
RESULTS
There were no signiﬁcant baseline differences between
the 2 groups in terms of age, disease stage at diagnosis,
response to induction, number of prior therapies, donor type,
stem cell source, and time from diagnosis to RIC-alloHCT. The
patients in this study represent a heavily pretreated popu-
lation inwhich the majority of patients had undergone high-
dose chemotherapy and autoHCT; the median number of
prior regimens was 4. The ratio of matched related donors to
matched unrelated donors in each group was roughly one
half. Graft-versus-host disease (GVHD) prophylaxis differed
slightly between the 2 groups because of an institutional
shift to tacrolimus/sirolimus in 2005. Although the median
number of prior regimens was the same, the no-BV group
received more combination chemotherapy and radiotherapy
(Table 1). The 2 groups also differed in terms of disease status
at the time of RIC-alloHCT and HCT-CI score. The median
HCT-CI score was signiﬁcantly better in the BV group (0
versus 2, P < .01) and patients in this group were also more
likely to be in complete remission before RIC-alloHCT (28.6%
versus 4.3%, P ¼ .04).There were no signiﬁcant differences between groups in
terms of engraftment or acute/chronic GVHD incidence. All
patients engrafted, with median time to absolute neutrophil
count  500 cells/mL of 14 days (range, 11 to 21) in the BV
Figure 1. Outcomes. N ¼ 44 patients. Surviving patients in the BV group (n ¼ 21) had median follow-up of 29.9 months, No-BV group (n ¼ 23) had median follow-up
of 85.3 months. (A) Shows Kaplan-Meier survival probabilities for PFS for BV group (solid line) and no-BV group (dashed line). PFS was deﬁned as time from stem cell
infusion to recurrence, progression, or death from any cause, whichever occurred ﬁrst. (B) Shows OS for BV group (solid line) and no-BV group (dashed line). OS was
measured from stem cell infusion to death from any cause. (C) Shows cumulative incidence of nonrelapse mortality for BV group (solid line) and no-BV group (dashed
line). NRM was measured from transplantation to death from any cause other than disease relapse or progression. (D) Shows the cumulative incidence of relapse/
progression for BV group (solid line) and no-BV group (dashed line). The cumulative incidence of relapse/progression was deﬁned as time from stem cell infusion to
recurrence or progression. Relapse/progression and NRM were calculated as competing risks.
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median time to platelet count >20,000 cells/mL without
transfusion support was 13 days (range, 11 to 26) in the BV
group and 13 days (range, 8 to 35) in the no-BV group. All
patients in both groups achieved > 99% donor chimerism by
day þ30. Acute GVHD occurred in 7 of 21 patients (33.3%) in
the BV group and 13 of 23 patients (56.5%) in the no-BV
group. The cumulative incidence of acute GVHD grades II to
IVwas 23.8% (95% CI, 8.4 to 43.6) in the BV group versus 47.8%
(95% CI, 26.2 to 66.7) in the no-BV group (P¼ .06). For chronic
GVHD, the 2-year cumulative incidence was 70.0% (95% CI,
43.3 to 85.9) for the BV group and 65.2% (95% CI, 40.0 to 81.9)
for the no-BV group (P ¼ .56).
Stratiﬁed outcome curves are shown in Figure 1. For the
BV-treated group, with a median follow-up of 29.9 months
(range, 12.4 to 48.5) in surviving patients, the 2-year PFS was
59.3% (95% CI, 33.9 to 77.7), 2-year OS was 71.1% (95% CI, 43.2
to 87),100-day NRMwas 0%,1-year NRMwas 9.5% (95% CI, 2.5
to 35.6), and the 2-year relapse/progression incidence was
23.8% (95% CI, 11.1 to 51.2). Surviving patients in the no-BV
group had longer follow-up (median, 85.3 months; range,
51.5 to 103.3) because of the time-period difference. In the no-
BV group, the 2-year PFS was 26.1% (95% CI, 10.6 to 44.7), 2-
year OS was 56.5% (95% CI, 34.3 to 73.8), 100-day NRM was
4.3% (95% CI, .6 to 29.6), and 1-year NRMwas 17.4% (95% CI, 7.1
to 42.4). The cumulative incidence of relapse/progression at
2 years was 56.5% (95% CI, 39.5 to 80.9). The BV group showed
improvement in 2-year PFS (59.3% versus 26.1%, P¼ .04) and a
reduction in 2-year relapse/progression incidence (23.8%
versus 56.5%, P ¼ .03) compared with the no-BV group.
We evaluated regimen-related toxicities in both groups
using the Bearman toxicity scale through day þ100. There
were no grade III to IV events in the BV group, and there were7 grade III events among 4 patients in the no-BV group:
bladder (n ¼ 1), gastrointestinal (n ¼ 1), pulmonary/renal
(n¼ 1), and pulmonary/renal/stomatitis (n¼ 1). In the no-BV
group, there were also an increased number of comorbid
conditions: median HCT-CI of 2. In the BV group, fewer pa-
tients received multiagent salvage chemotherapies, possibly
because of substitution of BV for a combination regimen.
Indeed, we found that patients in the BV group had a lower
median HCT-CI score (median, 0), higher percentage of pa-
tients in complete remission (CR) (28.9%), and fewer peri-
transplantation toxicities (n ¼ 0 grade III to IV events). Of
the baseline patient, disease, and treatment characteristics
evaluated by Cox univariate analysis, only previous BV
exposure (yes/no) (hazard ratio, 2.27; 95% CI, 1.04 to 4.97;
P ¼ .04) and HCT-CI score (hazard ratio, 1.40; 95% CI, 1.03 to
1.90; P ¼ .03) modeled as a continuous variable were pre-
dictive of PFS.
DISCUSSION
The median OS of patients who relapse after autoHCT is
only 2.4 years [11]. AlloHCT has been the only option that
offers the possibility of long-term remission. Unfortunately,
this approach is limited by age, performance status, and
comorbidities of patients who have been previously exposed
to many rounds of combination chemotherapy. Historical
data also show a relatively high relapse rate. Some studies
report a low 2-year PFS (23% to 32%) for HL patients under-
going alloHCT [4,12,13], whereas others report 4-year PFS in a
similar range (24% to 39%) for HL patients undergoing
alloHCT [14,15]. This low PFS could result from lack of disease
control before alloHCT, as many patients were not in CR or
had chemoresistant disease. BV, an antibody-drug conjugate,
was granted accelerated approval by the FDA in 2011 for the
R. Chen et al. / Biol Blood Marrow Transplant 20 (2014) 1841e1868 1867treatment of relapsed/refractory HL after failure of auto-HCT
[1]. In the pivotal phase II trial that lead to its approval, pa-
tients who achieved responses on BV were allowed to come
off trial to proceed to alloHCT.We had previously reported on
the successful use of BV as a bridge to alloHCT [5]. This report
serves to (1) update that experience with longer follow-up,
(2) provide a more homogenous patient population, and
(3) compare this group with an historical cohort. Patients in
the current report had 1 additional year of follow-up and,
thus, we are able to provide 2-year PFS data. All the patients
in this report received ﬂudarabine and melphalan as a con-
ditioning regimen and had matched related or unrelated
donor stem cell sources (no cord or haploidentical donors).
When compared with our own historical cohort (consec-
utive case series) who received the same conditioning regi-
mens and stem cell sources, we were able to show that BV
before alloHCT improves HCT-CI, peri-transplant toxicities,
and disease status at alloHCT. We believe that these 2 groups
of patients were essentially matched, with the exception of BV
exposure. This is evident by their stage, age, response to in-
duction, previous auto-HCT, and median number of previous
treatments. All the patients had relapsed/refractory disease
before receiving BV in the BV group or before salvage com-
bination chemotherapy in the no-BV group.
In the pivotal phase II trial, BV had a high overall response
rate and was well tolerated with a low toxicity proﬁle. The
no-BV group had a higher percentage of patients who
received ESHAP, a combination of etoposide, methylpred-
nisolone (solumedrol), high-dose cytarabine (ara-C), and
cisplatin which is typically a second salvage chemotherapy
regimen. For these patients, who were relapsed/refractory to
multiple chemotherapy regimens, another round of salvage
chemotherapy could cause greater harm than the beneﬁt it
adds. Indeed, patients in the no-BV arm had worse HCT-CI
scores and more grade III to IV Bearman scale peri-
transplantation toxicities. It is also not surprising that more
patients in the BV group were in CR at the time of alloHCT
(statistically signiﬁcant). There were some subtle differences
between the groups that were not statistically signiﬁcant.
The no-BV group had receivedmore radiation therapy, which
could be because of the use of radiation to achieve disease
control before alloHCT. The BV group also had longer time to
alloHCT. This could be explained by the fact that BV can be
given for multiple cycles because of its relative low toxicity
proﬁle, whereas multiagent salvage chemotherapies are only
given for a maximum of 2 to 3 cycles before alloHCT. Also,
some patients who had achieved CR/partial response waited
to undergo alloHCT by choice. Not every patient in the BV
group proceeded to alloHCT immediately after BV. Six pa-
tients progressed while on BV treatment and some received
additional chemotherapy. We did not exclude these patients
from the analysis, as they were still given BV and achieved
response to BV initially.
It is not surprising that we found improved 2-year PFS and
cumulative incidence of relapse/progression in the BV group,
as multiple previous reports show that improved disease
status at transplantation and HCT-CI are associated with
improved PFS after alloHCT [6,12,16-18]. We understand that
this study is not a prospective trial and, therefore, suffers from
biases inherent in retrospective analyses. However, this
comparison was performed on 2 consecutive case series of
patients from 2003 to 2008 (pre-BV era) and 2009 to 2012
(post-BV area). Essentially, this reﬂects actual practice pat-
terns occurring at our institution for the past 10 years and
shows that alloHCToutcomes have improved in the BV era. OSdid not change signiﬁcantly at the 2-year time point. Of the 7
deaths in the BV group, 2 were due to disease progression, 2
due to GVHD, 1 due to infection, and 2 due to cardiovascular
events (presumed long-term complications of radiation ther-
apy). Of the 17 deaths in the no-BV group, 10 were due to
disease progression, 4 due to GVHD, 1 due to infection, and 2
due to other causes. If the improvement in relapse rate con-
tinues after the 2-year time point, it is very likely we will see
an improvement in OS, as most of the deaths in the no-BV
group were due to disease progression. We will continue to
follow these patients and it is possible that we will be able to
see improvement in OS at the 3- or 5-year time points.
Although our 2-year PFS estimate of 59.3% is less striking
than the 1-year PFS of 92.3% seen in our initial report on BV
salvage before RIC-alloHCT [5], we felt it important to update
our initial observations for increased accuracy resulting from
longer follow-up, to evaluate outcomes in a more homoge-
nous patient population, and to compare the outcomes of BV
patients to a BV-naïve case series. There have been few other
reports on BV before alloHCT [19,20], and our current study
represents the largest series of patients with the longest
follow-up successfully undergoing RIC-alloHCT after BV
therapy. The patients in our BV and no-BV groups are well
matched at diagnosis and at relapse, and diverge in their
disease characteristics only after BV treatment. We believe
these data demonstrate that BV allows clinicians to improve
disease status at transplantation, median HCT-CI, and peri-
transplantation severe toxicities. These, in turn, are associ-
ated with an improvement in 2-year PFS and cumulative
incidence of relapse/progression. For patients with relapsed/
refractory HLwho are considered candidates for RIC-alloHCT,
BV is a reasonable option as a bridge to RIC-alloHCT.ACKNOWLEDGMENTS
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